Trials / Terminated

TerminatedNCT00362505

Safety and Antiviral Activity of Clevudine in Patients Who Have Completed the L-FMAU-301 or L-FMAU-302 Trials

An Open-label, Phase III Clinical Trial to Evaluate the Safety and Antiviral Activity of Clevudine in Chronic Hepatitis B Patients Who Have Completed the L-FMAU-301 or L-FMAU-302 Trials

Status: Terminated
Phase: Phase 3
Study type: Interventional
Enrollment: —

Sponsor: Bukwang Pharmaceutical · Industry
Sex: All
Age: —
Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine safety and efficacy of clevudine 10 mg qd for 24 weeks after completion of 24-week treatment with clevudine 30 mg qd with 12 weeks follow-up period

Conditions

Hepatitis B

Interventions

Type	Name	Description
DRUG	Clevudine

Timeline

Start date: 2004-06-01
Completion: 2006-03-01
First posted: 2006-08-10
Last updated: 2017-02-01

Locations

32 sites across 1 country: South Korea

Source: ClinicalTrials.gov record NCT00362505. Inclusion in this directory is not an endorsement.